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Abstract
Diabetes mellitus (DM) is a risk factor for the development of cognitive impairment, 
when unsatisfactory glycemic control is associated with glioma biomarkers and changes 
in neuronal integrity. Given some limitations in the performance of neuropsychological 
testing, it is important to indicate specific markers of brain damage.
Keywords: diabetes mellitus, cognitive disorders, neurospecific proteins, magnetic 
resonance imagining
1. Introduction
One of the most significant in the social aspect of the categories in the population was and 
still is patients with diabetes mellitus (DM). According to the estimates of the International 
Diabetes Federation, there are 415 million people with diabetes in the world in 2015, and 
by 2040, it is projected to grow to 642 million people. In the last decade, it has been proven 
that diabetes mellitus causes disturbances in the functioning of regulatory systems and the 
psychological and emotional state has both direct and indirect effects on the development of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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complications from the central nervous system, manifested by morphological and functional 
disorders. The reflection of brain neuroplasticity is the dynamics of cognitive impairment.
According to the latest revision of the international guidelines for the diagnosis of mental 
disorders, cognitive disorders include a decrease in one or more higher cerebral functions, in 
comparison with the premorbid level, that provide the processes of perception, preservation, 
transformation, and transmission of information. The presence of cognitive impairments has 
an extremely negative effect on the quality of life of the patient and their immediate fam-
ily and complicates the treatment of concomitant diseases and the conduct of rehabilitation 
activities. Therefore, timely diagnostics and the earliest possible initiation of therapy for exist-
ing cognitive disorders are very important.
Figure 1 shows that the effect of dysglycemia in the debut of type 1 diabetes mellitus, espe-
cially in childhood, leads to a statistically more significant pronounced cognitive impairment, 
as well as structural changes in the brain over time [1].
To date, it is urgent to search for a quick, simple, and well-tried method for diagnosing cogni-
tive impairment, taking into account the minimum costs. One of the promising methods that 
can be considered is the identification of neurospecific proteins, which are signals of brain dam-
age [2–4]. To diagnose central nervous system diseases, magnetic resonance methods of brain 
examination are used as additional techniques for detecting morphological changes [5, 6].
Figure 1. The trajectory of disorders from the brain’s magnetic resonance imaging data in patients with type 1 diabetes 
mellitus is associated with loss of brain volume (blue line, evolution of brain volumes with age in the general population, and 
red line, estimated trajectories for type 1 diabetes mellitus (A), and brain atrophy is a loss of neuron communication (B)) [1].
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2. Pilot study: identification of cognitive impairment markers 
(neurospecific proteins, magnetic resonance tomography) in patients 
with type 1 diabetes mellitus
The study of cognitive dysfunction in patients with type 1 DM was carried out at the clinical 
bases of the Departments of Endocrinology and Diabetology, Neurology and Neurosurgery of 
the Siberian State Medical University, and the plan and the study were in full compliance with the 
principles of Good Clinical Practice (GCP) and Helsinki Declaration (including amendments).
The study included 116 patients with type 1 diabetes mellitus at the age of 22.4 ± 4.6 years, 
58 men and 58 women, and the duration of the disease was 6.6 ± 3.9 years. The control group 
consisted of 29 healthy people, aged 22.4 ± 4.8 years, 14 men and 15 women, without acute 
and chronic diseases. Inclusion criteria are patients with type 1 diabetes mellitus at the age of 
16–30 and signed informed consent of the patient to participate in the study.
Exclusion criteria are hypoglycemic and ketoacidotic coma for 1 year prior to study; presence 
of hematological, oncological, and serious infectious diseases; condition after severe cranioce-
rebral injuries and surgeries; participation in other clinical trials in the last 30 days; and now 
refusal to sign an informed consent of the patient to participate in the study.
To detect violations of carbohydrate metabolism, glucose was determined by the glucose 
oxidase method on the biochemical analyzer “Hitachi 912” (Hoffmann-La Roche Ltd./Roche 
Diagnostics GmbH, Germany). HbA1c content was analyxed in capillary blood - by liquid 
chromatography method on DS5 Glycomat analyzer (Drew Scientific, the Netherlands).
With the biochemical methods of research, the content of neurospecific proteins in plasma was 
determined. To analyze the quantitative content of the S100 protein (S100A1B + S100BB), a 
kit was used (FujirebioS100 EIA, BioC himMak, Russia). GFAP was determined by enzyme 
immunoassay using a standard protocol using a reagent kit from the manufacturer (BioVendor 
Laboratory Medicine, Inc., Germany). The myelin basic protein (MBP) level was studied using 
the “DSL-10-58,200” kit (BioChimMak, Russia). The complex of mandatory diagnostic methods 
included magnetic resonance imaging of the brain on the Harmony 1.0 T apparatus (Siemens, 
Germany) by MDCS-Tomsk Ltd., which was carried out according to the standard procedure 
in the axial, sagittal, and coronal projections using T2 (TR (time of repetition) 4932 ms, TE 
(Echotime) 90 ms) and T1 (TR 280 ms, TE 6.1 ms) and using programs with free water signal 
suppression fluid-attenuated inversion recovery (FLAIR; TR 8000 ms, TE 105 ms, TI (time in 
version) 2200 ms). Evaluation of gliosis foci of brain substance was carried out according to the 
size and quantity in the frontal (subcortical, paraventricular), temporal (white matter, hippo-
campal area), parietal (subcortical, paraventricular), and occipital (subcortical, paraventricular) 
areas. Taking into account the classification of F. Fazekas, in the modification of NN Yakhno, a 
quantitative gradation of focal changes in the white matter was carried out [7]. The severity of 
leukoareosis was assessed in scores proposed by Liu et al. [8]. For the quantitative evaluation of 
the expansion of perivascular spaces, the estimated scale of MacLullich [9] was used.
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Screening for mild and moderate cognitive impairment was performed using the MoCA test, 
which assesses various cognitive functions: visual–spatial perception (the test of drawing a 
clock and a cube); executive functions (task of creating an alternating path and testing the 
ability to abstract thinking); attention, concentration, and operational memory (serial subtrac-
tion by 7 and playback of the digital series in forward and reverse order); and speech (naming 
animals, repetition of two syntactically complex sentences) and the specificity of the method 
is 90% [10]. Statistical processing of the obtained data was carried out using the application 
software package R Systems International.
Characteristics of the carbohydrate metabolism parameters showed a difference in the 
parameters between the main group and the control group. The average level of HbA1c 
in patients with type 1 diabetes mellitus was 8.8 ± 1.8%, and the average level of fasting 
glycemia was 11.5 ± 5.0 mmol/l. This indicated an unsatisfactory metabolic control. In addi-
tion, differences in the parameters of carbohydrate metabolism were revealed taking into 
account gender characteristics, so women had better values of fasting and HbA1c glycemia 
than men.
In the control group, healthy volunteers complained of asthenic syndrome (37.9%), manifes-
tations of which were fatigue (13.3%), dizziness (6.7%), and headache (16.9%). Patients with 
type 1 diabetes mellitus also had these complaints but in a more pronounced form. The next 
in frequency recorded cephalic syndrome, occurring in 25.9% of patients. Among the localiza-
tions, the most frequent areas were occipital (60%) and temporal (2.6%) areas, with the same 
frequency; headache was diffuse and was found in the frontal region. The most common 
cause of headache was overexertion due to stress. In addition, complaints were found from 
the peripheral nervous system on paresthesia (37.9%), pain (22.4%), numbness (12.1%), and 
convulsions in the lower extremities (6.9%). Often, patients with type 1 diabetes mellitus com-
plained of memory loss. This was manifested by the difficulty in concentrating, remember-
ing new information, and solving short-term problems. The objective status of patients was 
characterized by autonomic symptoms, manifested as anxiety. Neurological symptoms of the 
examined patients were mainly represented by disorders of the autonomic nervous system, 
namely, distal and diffuse hyperhidrosis (in 43.1% of patients) and persistent red spilled der-
mographism (in 22.4% of patients) in the face, neck, and décolleté area. The manifestations 
of lesions of the peripheral nervous system were in the form of diabetic polyneuropathy. 
Sensory disorders were noted from the lower extremities in 62% of cases and the upper ones 
in 27.5%. A clinical study of random movements in the limbs with an evaluation of the tone 
revealed a hypotonia of the upper limbs in 51.7% and lower in 34.5% of cases.
2.1. An analysis of the neuropsychological status in patients with type 1 diabetes 
mellitus
This study based on the results of a screening MoCA test showed that type 1 diabetes mellitus 
may manifest cognitive dysfunction in 72.4% of cases. Thus, one-third of patients with type 1 
diabetes mellitus had cognitive dysfunction compared to the control group (Table 1).
When assessing the individual tasks of the MoCA test, a statistically significant decrease in 
the parameter of the short-term memory was registered. The exercise included memorizing 
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five words and repeating them after subsequent tasks in about 5 minutes. Patients with type 
1 diabetes mellitus had difficulty in reproducing words, were confused, and invented new 
words. At the same time, this task was performed unsatisfactorily by both men and women. 
The attention function was evaluated using two tasks. The first task is a numerical series, that 
is, a repetition of the numbers mentioned. With this task men were worse than women. The 
second task is the serial subtraction by 7, which was given equally hard.
2.2. Analysis of parameters of neurospecific proteins in patients with type 1 diabetes 
mellitus
As a result of the analysis, a significant increase in all studied proteins was revealed in 
patients with type 1 diabetes mellitus, S100, MBP, and GFAP, compared to the control group 
(p < 0.001) (Table 2).
The levels of neurospecific proteins, depending on the duration of the disease, had fluc-
tuations. So, the S100 protein was higher in patients with a short duration of the disease 
(1–4 years) and the smallest with duration of the disease for more than 15 years. While MBP 
had an equally stable level in patients with different durations of type 1 diabetes mellitus. 
The fluctuations in the level of GFAP were also insignificant and tended to decrease with 
increasing duration of the disease. According to our study, in women, the level of GFAP was 
significantly lower than in men (U = 643.0, z = −2.4, p < 0.05).
Parameters Type 1 DM (n = 98) Control group (n = 29)
Alternating Trail Making 3.0 ± 0.4 3.0 ± 0.1
Alternating path (drawing) 3.0 ± 0.8 3.0 ± 0.1
Cube (drawing) 3.0* ± 1.3 5.0 ± 0.2
Clock (drawing) 2.0* ± 0.6 2.0 ± 0.1
Naming 1.0 ± 0.9 1.0 ± 0.1
Memory 2.0* ± 0.8 3.0 ± 0.1
Number series 2.0 ± 0.4 1.8 ± 0.4
Concentration 1.0 ± 0.8 0.8 ± 0.3
Serial subtraction by 7 2.0 ± 0.4 2.0 ± 0.1
Repeat suggestions 6.0 ± 0.2 6.0 ± 0.1
Fluency of speech 25.0* ± 0.8 30* ± 0.4
Abstraction 3.0 ± 0.4 3.0 ± 0.1
Orientation 3.0 ± 0.8 3.0 ± 0.1
Sum of points 3.0* ± 1.3 5.0 ± 0.2
Note: The significance of differences between the control group and patients with type 1 diabetes mellitus at the 
parameters of MoCA test: *p < 0.001, m is the median, and SD is the standard deviation.
Table 1. Characteristics of the MoCA test parameters in patients with type 1 diabetes mellitus and control group.
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2.3. Characteristics of magnetic resonance imaging of the brain in patients with type 
1 diabetes mellitus and in control group
Analysis of magnetic resonance imaging of the brain revealed indirect signs of atrophy of 
the gray matter of the frontal and partly parietal lobes. Thus, in patients with type 1 diabetes 
mellitus, arachnoid changes  (93.1%) and expansion of the convective liquor spaces (72.4%) 
were significantly more frequent. In the control group, changes in thearachnoid changes were 
detected in 67% (Table 3). Figure 2 in the coronal projection (mode T2) shows the expansion 
of the convective fluidic spaces.
MRI of the brain showed the presence of gliosis sites in 15.5% of cases and lesions of leukoare-
osis in 18.3% of cases in patients with type 1 diabetes mellitus, whereas in the control group 
no changes were revealed (Table 3). In Figure 3, in the axial projection (FLAIR mode) in the 
white matter of the frontal and parietal lobes, small foci of a dystrophic character are defined.
In Figure 4, coronal lesions are identified in the coronal projection. According to the classifica-
tion proposed by Lui, the severity of leukoareosis is two points.
Perivascular spaces of Virchow-Robin are a morphological and functional structure of the cen-
tral nervous system; therefore, various versions of their dilatation can be an indirect reflection 
of changes in the brain substance and indicate atrophy. In the study, expansion of Virchow-
Robin spaces occurred in 80.6% of cases in patients with type 1 diabetes mellitus, which was 
significantly higher than in the control group, 6.7%, respectively (Table 3).
These changes are shown in Figure 5, where in the coronal projection in the thalamus region, 
nonuniformly expanded Virchow-Robin spaces are determined from both sides. Given the 
classification of MacLullich, they are estimated at 2 points.
Thus, according to MRI, the morphological changes in the brain in patients with type 1 dia-
betes mellitus are represented by arachnoid changes in the liquor cystic, the expansion of the 
convective spaces, and the Virchow-Robin spaces of the brain.
2.4. Interrelations of clinical-metabolic, neuropsychological features and markers of 
cognitive impairment in patients with type 1 diabetes mellitus
When evaluating the results, a negative correlation was found between the fasting glycemia 
and HbA1c levels with the test parameters responsible for memory and attention (task for 
Neuro-specific proteins Type 1 DM (n = 98) Control group (n = 29)
0.13 ± 0.05* 0.10 ± 0.036
Myelin basic protein (MBP) (ng/ml) 0.12 ± 0.04* 0.08 ± 0.033
Glial fibrillary acidic protein (GFAP) (ng/ml) 125.65 ± 66.97* 62.85 ± 19.66
S100 (ng/ml) 0.13 ± 0.05* 0.10 ± 0.036
Note: The significance of differences between the control group and patients with type 1 diabetes mellitus at the level: 
*p < 0.01.
Table 2. Characteristic levels of neurospecific proteins in patients with type 1 diabetes mellitus and the control group.
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number series and serial subtraction). That is, the higher the levels of carbohydrate metabo-
lism, the worse the memory and attention are (Table 4). On the part of other indicators of the 
MoCA, the connection was not found.
In assignments for attention, a negative correlation was found only with the protein S100 
(r = −0.3, p = 0.02, r = −0.3, p = 0.004). We revealed relationship between the decrease in memory 
functions and the increase in the level was the decrease in memory functions with a simultane-
ous increase in the level of the studied neurospecific proteins, that is, the presence of a nega-
tive correlation with the S100 (r = −0.4, p = 0.001), GFAP (r = −0.4, p = 0.02), and MBP (r = −0.5, 
p = 0.001) proteins.
To assess the significance for the diagnosis of proteins, sensitivity and specificity were 
assessed. It was shown that they are highly specific and have a moderate sensitivity (Table 5).
Thus, in patients with type 1 diabetes mellitus and identified cognitive dysfunction, an 
increase in the content of all neurospecific proteins against hyperglycemia is characteristic. 
Based on the assessment of specificity and sensitivity, a high level of diagnostic significance 
of neurospecific proteins is shown, which makes it possible to use them in general medical 
practice.
When evaluating the effect of carbohydrate metabolism parameters on the change in the results of 
magnetic resonance imaging of the brain in patients with type 1 diabetes mellitus, positive correla-
tion relationships were recorded. Thus, moderate strengths between the expansion of the cerebro-
spinal fluid and the level of HbA1c (r = 0.6, p = 0.001) and fasting glycemia (r = 0.5, p = 0.001) were 
revealed. In addition, connections have also been found with extensions of the Virchow-Robin 
spaces (r = 0.6, p = 0.001, r = 0.5, p = 0.001) and convective spaces (r = 0.5, p = 0.004, r = 0.3, p = 0.003) 
with the indices of carbohydrate metabolism. Analysis of the effect of cognitive dysfunction on the 
results of magnetic resonance imaging of the brain showed the presence of a bond. A correlation 
was found between memory loss in patients with type 1 diabetes mellitus and the expansion of 
arachnoid (r = −0.3, p = 0.02) and Virchow-Robin spaces (r = −0.3, p = 0.007). A link was also found 
between the decrease in attention and atrophy of gray matter in the brain in patients with type 1 
diabetes mellitus. Patients with an expansion of arachnoid (r = −0.3, p = 0.007), convective spaces 
Indicators Type 1 DM
(n = 98)
Control group 
(n = 29)
χ2
Arachnoidal changes in the cerebrospinal fluid 108 (93.1%) 2 (6.7%) χ2; p
Expansion of convective fluidic spaces 71 (72.4%) 0 (0%) χ2 = 63.84; p = 0.01
Expansion of Virchow-Robin spaces 79 (80.6%) 2 (6.7%) χ2 = 43.4; p = 0.01
Gliosis 15 (15.3%) 0 (0%) χ2 = 4.32;
p = 0.01
Leukoareosis 18 (18.3%) 0 (0%) χ2 = 5.19;
p = 0.02
Note: The significance of the differences between the control group and patients with type 1 diabetes mellitus at the 
level: *p < 0.001.
Table 3. Characterization of the magnetic resonance pattern of the brain of patients with type 1 diabetes mellitus in 
comparison with the control group.
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(r = −0.3, p = 0.007), and Virchow -Robin spaces were worse performing the tasks for attention 
(“numerical series” and “serial subtraction” by 7) (r = −0.3, p = 0.007). To assess the significance 
of changes reflected in magnetic resonance imaging of the brain in patients with type 1 diabetes 
Figure 2. A snapshot of the brain in the coronal projection in T2 mode is determined by the expansion of the convective 
fluidic spaces (photo by Matveeva, 2015).
Figure 3. A snapshot of the brain in the axial projection in the FLAIR mode in the white matter of the frontal and parietal 
lobes is determined by small foci of increased signal on T2 and FLAIR, without signs of perifocal edema, of a dystrophic 
nature (photo by Matveeva, 2015).
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 mellitus, sensitivity and specificity were assessed. Morphological signs of gray matter atrophy 
of the brain, namely, arachnoid changes in the liquor cystic nature, widening of the convective 
spaces, and Virchow-Robin spaces, are highly sensitive, but are not specific (Table 6).
Figure 4. A snapshot of the brain in the coronal projection in T2 mode in the white matter of the frontal and parietal 
lobes,; the focus of the leukoareosis is determined by the severity of two points [8] (photo by Matveeva, 2015).
Figure 5. A snapshot of the brain in the coronal projection in the T2 mode in the thalamus region on both sides of unevenly 
expanded Virchow-Robin spaces is determined (two points according to MacLullich (2003)) (photo by Matveeva, 2015).
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Thus, the obtained data showed the relationship of gray matter atrophy of the brain magnetic 
resonance imaging in patients with type 1 diabetes mellitus with chronic hyperglycemia and 
cognitive impairment. In addition, nonspecificity of the revealed changes was revealed in 
patients with type 1 diabetes mellitus in comparison with the control group.
2.5. Comparison of the results and literature data
As methods for finding markers of cognitive impairments, neurophysiological and biochemical 
methods with certain limitations are described in the literature. We conducted a comprehensive 
study that included as a neuropsychological technique a screening MoCA test, an evaluation 
of neurospecific proteins, and a magnetic resonance imaging data in patients with type 1 dia-
betes mellitus. In our study, screening for cognitive dysfunction with the MoCA test showed a 
decrease in only memory function and attention in patients with type 1 diabetes mellitus, while 
other functions were not impaired. Analysis of the relationship of cognitive dysfunction with 
sex, age, and duration of the disease did not reveal these. The results confirm the meta-analysis 
conducted in 2007 by Brands and Bissels, where it was shown that there were moderate cogni-
tive impairments that did not manifest themselves in daily life, but influenced the professional 
sphere, where high concentration, attention, and memory are required [1]. The question of the 
metabolic component as the cause of the development of cognitive dysfunction for a long time 
was debatable. The data obtained in this study on cognitive dysfunction allowed a mathemati-
cal analysis of the effect of carbohydrate metabolism on it and the effect of hyperglycemia on 
the development of cognitive dysfunction in patients with type 1 diabetes mellitus. In patients 
with type 1 diabetes mellitus, Russian scientists also noted a decrease in memory function, 
which worsened with chronic hyperglycemia [11]. In the endocrine community, a large-scale 
study on the control and complications of diabetes (DCCT/EDIC) is considered authoritative 
[12], which confirmed the absence of the effect of hypoglycemia on the development of cogni-
tive dysfunction. The analysis of additional markers of cognitive dysfunction was carried out 
with the help of biochemical methods, which made it possible to evaluate neurospecific pro-
teins. In patients with type 1 diabetes mellitus, S100, GFAP, and MBP proteins were elevated, 
which may indicate microscopic brain damage. One of the proteins studied was S100; as a 
result, it was found that patients with unsatisfactory control of carbohydrate metabolism had 
higher levels of S100 protein. So, a positive correlation of S100 protein with the HbA1c level 
and fasting glycemia was found, which can prove the role of chronic hyperglycemia in the 
dysmetabolic processes of the brain. A study of this protein in patients with type 1 diabetes 
mellitus was also conducted by Strachan (2000) [13], but significant changes in groups with 
S100 MBP GFAP
HbA1с r = −0.69; p = 0.01 r = −0.30; p = 0.01 r = −0.35; p = 0.04
Fast glucose r = −0.45; p = 0.02 r = −0.36; p = 0.01 r = −0.31; p = 0.01
Note: The significance of the correlation: *p < 0.05.
Table 4. Interrelation of the parameters of the MoCA test with HbA1c and fasting glycemia.
Cognitive Disorders24
type 1 diabetes have not been found [13]. Comparison of MBP with HbA1c and fasting glucose 
showed a positive correlation. Most likely, fluctuations in glycemia caused damage to the oli-
godendrocytes of the brain with the release of more MBP. In the literature, such data were not 
found. A third, but no less important, protein was the GFAP marker for astrocyte damage. In 
our study, a positive correlation was found between the parameters of carbohydrate metabo-
lism and the level of GFAP, which indicates the effect of hyperglycemia on the mechanisms of 
apoptosis of astrocytes. The results obtained are confirmed by the studies of F.E. Saravia and 
coauthors; they showed the effect of hyperglycemia on higher amounts of GFAP during the 
manifestation of type 1 diabetes mellitus, when uncompensated hyperglycemia is observed, 
that is, hyperglycemia has the greatest impact on brain damage [14].
As an additional method for evaluating cognitive dysfunction, magnetic resonance imaging 
of the brain was proposed; this was performed according to a standard procedure, that is, as 
screening without additional functional options. As a result of the study, signs of cerebral 
atrophy were found, namely, arachnoid changes in the liquor cystic and expansion of the 
convective fluidic spaces, which correlates with the data of the special literature [15]. The 
data obtained during the study confirm the presence of indirect signs of cerebral atrophy 
in patients with type 1 diabetes mellitus of a nonspecific type. In addition, the literature 
addresses the duration of type 1 diabetes mellitus and the possible weighting of morpho-
logical changes. In our study, the association with age and duration of the disease was not 
revealed. However, Trofimova et al. found that the degree of severity of structural changes in 
the brain substance is associated with the progression of type 1 diabetes mellitus and with an 
increase in the age of the patients [16]. In the study, an evaluation of the influence of glycemia 
on the morphological structure of the brain showed the relationship of hyperglycemia with 
the expansion of fluidic spaces, convective spaces, and Virchow-Robin spaces. In the litera-
ture, cases of atrophy of the gray matter of the brain, which was detected predominantly in 
the frontal lobes and central areas of the parietal lobes [17], is described, both in acute cases 
of ketoacidosis and prolonged increase in HbA1c. In addition to the relationship with the 
parameters of carbohydrate metabolism, the analysis revealed the relationship of cognitive 
impairments to brain atrophy, which was also noted in the publications of Hoogma [18]. In 
our study, there was a correlation of memory loss in patients with type 1 diabetes mellitus 
with an expansion of arachnoid and Virchow-Robin spaces (r = −0.3, p = 0.007). Also, a con-
nection was found between poor performances of tasks for attention (numerical series and 
serial subtraction by 7) by patients with the expansion of arachnoid, convective spaces, and 
Virchow-Robin spaces (r = −0.3, p = 0.007).
NSP Value Sensitivity (%) Specificity (%)
MBP ng/ml 0.1025 45.7 81
GFAP ng/ml 0.106 41.3 76.2
S100 ng/ml 65.15 58.7 95.2
Table 5. Characteristics of specificity and sensitivity of neurospecific proteins as markers of cognitive dysfunction.
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3. Pilot study: the role of glycemia variability in development of 
cognitive disorders in patients with type 1 diabetes mellitus
Design: observational, transverse, and one-stage study. Clinical characteristics of patients is 
as follows: 30 patients with type 1 diabetes mellitus at the age of 27 (22–31) years and duration 
of the disease 17 (5–23) years; among them 14 men and 16 women were examined. Patients 
were divided into two groups: the first group (main)—with the presence of cognitive impair-
ment, and the second group (control)—with normal cognitive functions.
For the diagnosis of fluctuations in the glucose level, continuous monitoring of glycemia was 
conducted using the iPro2 device (Medtronic, USA) and the CareLink iPro™ software, as well 
as the Medtronic MiniLink and MMT-700 transmitter, and the Medtronic Diabetes CareLink 
USB device. Fixation of data on the level of glycemia was carried out at a 5-minute interval for 
72 hours using a system of constant monitoring of glycemia. We used the EasyGV calculator 
(version 9.0), proposed by Hill (2011) [26] (Figure 6).
The following glucose variability values were assessed: mean glycemic mean (MEAN), stan-
dard deviation (SD), mean amplitude of glycemic fluctuation (MAGE), long-term glycemic 
index (CONGA), glycemia lability index (LI), hypoglycemia risk index (LBGI), an index of 
risk of hyperglycemia (HBGI), and average hourly rate of change in glycemia (MAG).
The study found that patients with type 1 diabetes mellitus among the main group of cogni-
tive disorders prevailed violation constructive praxis, memory, and attention. The average 
score in this group was 23.8 ± 0.66, while in the control group, it was 26.4 ± 0.13 points, respec-
tively (t = 3.6, p = 0.001) (Table 7). In the study of HbA1c in plasma, the mean level in the main 
group was 10.5 ± 1.3%, and in the control group 6.7 ± 0.23% (t = −2.5, p = 0.015).
The analysis of the GV indicators is presented in Table 8. There is a significant difference in 
MEAN, SD, CONGA, Gindex, LBGI, HBGI, MAGE, Mvalue, and MAG.
Correlation analysis shows that cognitive functions are generally affected by the level of HbA1c 
(χ2 = −0.450, p = 0.014), as well as the MEAN variability parameters (χ2 = −0.584, p = 0.001), SD 
(χ2 = 0.022, p = 0.022), CONGA (χ2 = −0.853, p = 0.001), Gindex (χ2 = −0.504, p = 0.005), LBGI (χ2 = 
−0.451, p = 0.014), HBGI (χ2 = −0.053, p = 0.003), MAGE (χ2 = −0.480, p = 0.008), Mvalue 
(χ2 = −0.593, p = 0.001), and MAG (χ2 = −0.573, p = 0.001).
Indicators Sensitivity (%) Specificity (%)
Arachnoidal changes in the cerebrospinal fluid 92 37
Expansion of convective fluidic spaces 73 26
Expansion of Virchow-Robin spaces 78 34
Gliosis 11 17
Leukoareosis 21 43
Table 6. Characteristics of specificity and sensitivity of signs of magnetic resonance imaging.
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On the constructive praxis in the job, the alternating path is most affected by the CONGA 
parameter (χ2 = −0.502, p = 0.006) and MAGE (χ2 = −0.555, p = 0.002), and the clock is MEAN 
(χ2 = −0.379, p = 0.043), LI (χ2 = −0.471, p = 0.010), Gindex (χ2 = −0.497, p = 0.006), LBGI (χ2 = −0.477, 
p = 0.009), HBGI (χ2 = − 0.384, p = 0.040), MAGE (χ2 = −0.386, p = 0.038), Mvalue (χ2 = −0.446, 
p = 0.002), and MAG (χ2 = −0.505, p = 0.005). To reduce memory, the MEAN indicator is most 
important (χ2 = −0.455, p = 0.013). Violation of the task of repeating the phrase depends on the 
level of HbA1c (χ2 = −0.390, p = 0.036), LI (χ2 = −0.463, p = 0.011), LBGI (χ2 = −0.604, p = 0.001), 
MAGE χ2 = −0.422, p = 0.031), Mvalue (χ2 = −0.483, p = 0.008), and MAG (χ2 = −0.501, p =0.002). 
The assignment of MoCA test (repeating speech) depends on the level of HbA1c.
The study showed a decrease in cognitive functions in (constructive praxis, repetition, and mem-
ory) in patients with type 1 diabetes mellitus. The currently available markers for the control of 
glycemia-HbA1c do not always reflect an excursion of hyperglycemia and hypoglycemia [19]. 
Figure 6. Example of a glycemic profile according to iPro data.
Parameters The main group The control group
Alternating path (drawing) 0.26 ± 0.11* 0.92 ± 0.07
Cube (drawing) 1.00 ± 0.00 1.00 ± 0.00
Clock (drawing) 2.60 ± 0.13* 2.14 ± 0.09
Naming 3.00 ± 0.00 3.00 ± 0.00
Memory 2.80 ± 0.32* 3.64 ± 0.24
Number series 1.80 ± 0.10 1.92 ± 0.71
Concentration 1.13 ± 0.13 1.14 ± 0.14
Serial subtraction by 7 2.66 ± 0.18 2.92 ± 0.07
Repeat suggestions 1.46 ± 0.13* 1.07 ± 0.07
Fluency of speech 0.66 ± 0.12 0.92 ± 0.07
Abstraction 1.53 ± 0.19 1.50 ± 0.13
Orientation 0.26 ± 0.11* 0.92 ± 0.07
Sum of points 1.00 ± 0.00 1.00 ± 0.00
Note: *p ≤ 0.05.
Table 7. Characteristics of parameters of the Montreal scale of cognitive functions in the main and control groups.
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Figure 7. Examples of models with the smallest squares indicating a negative relationship between a multi-scale SH, the 
volumes of regions of the brain, as well as cognitive functions: (A) the ratio between GVC2 and volume of GM in the left 
island cortex, (B) the ratio between GVC1 and GM volume in the right spindle-shaped gyrus, (C) the ratio between GVC2 
and GM volume in the left cingulate gyrus, and (D) the ratio between GVC2 and total cognitive performance (composite T) 
(SD, triangles; control, circles).
Parameters The main group The control group Significance
MEAN 9.17 (8.36–10.00) 7.25 (6.77–7.87) U = 29, p = 0.001
SD 4.54 (3.86–5.79) 2.95 (2.61–3.47) U = 26, p = 0.001
CONGA 6.66(5.77–7.81) 4.32 (4.15–4.51) t = −4.9, p = 0.001
LI 22.35 (20.76–92.99) 27.17(22.84–55.68) U = 98.5, p = 0.776
Gindex 56.41 (52.00–79.69) 45.50 (36.85–50.76) U = 43, p = 0.007
LBGI 11.16 (8.24–17.26) 6.77 (4.44–7.53) U = 53.5, p = 0.023
HBGI 13.19 (11.01–21.25) 8.00 (6.91–10.45) U = 43, p = 0.006
MAGE 4.86 ± 0.23 2.44 ± 0.13 U = 34, p = 0.002
Mvalue 28.38 (20.46–26.90) 14.43 (11.92–17.04) U = 124.5, p = 0.001
MAG 59.60 (53.54–88.43) 34.60 (30.83–42.17) t = −8.5, p = 0.001
Note: Mann-Whitney U test, Student’s t-test.
Table 8. Characteristics of VG indicators by groups.
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Patients with similar levels of HbA1c and average glucose values may have a significantly dif-
ferent daily variability in glycemia. In his study, Rizzo et al. showed that MAGE was associated 
with impaired cognitive functioning, regardless of the level of HbA1c among patients with dia-
betes (R = 0.83, p < 0.001) [20]. Although the mechanisms by which the variability of glycemia 
affects cognitive function are not clear, they can also be associated with oxidative stress. In this 
context, daily glucose fluctuations, such as peaks and falls, affect the development of oxida-
tive stress more than chronic hyperglycemia. The work of Abbatecola et al. also demonstrated 
that an increase in postprandial glucose variability is associated with attention impairment [21] 
(Figure 7).
Thus, the present study demonstrated a link between high HbA1c, glycemic variability, and 
cognitive function in patients with type 1 diabetes mellitus. Since dysglycemia is a risk fac-
tor for both mild to moderate cognitive impairment and dementia, the present data provide 
opportunities for interventional studies to stabilize glycemia, not only by reducing HbA1c but 
also leveling out acute glucose fluctuations.
4. Pilot study: magnetic resonance spectrometry as a method of 
estimation of brain metabolism in type 1 diabetes mellitus
The proton magnetic resonance multilocular spectroscopy of the brain was carried out on a 
MAGNETOM Symphony 1.5 T (Siemens) device with the relaxation time TE = 135, and the voxel 
volume was 1.5 cm3; the main spectra of choline (Cho), creatine/phosphocreatine (Cr, Cr2), and 
N-acetylaspartate (NAA) were analyzed [22]. With the help of the regional approach, the data of 
metabolites Cho (choline), creatine), Cr2 (phosphocreatine), NAA (N-acetylaspartate), localized 
in the hippocampal region on the left and right.
The study revealed that the average age of patients with type 1 diabetes mellitus was 26 ± 4.8 years, 
and the control group was 30 ± 6.4 years. When comparing patients with type 1 diabetes mellitus 
(30 people) and control group (18 people) in metabolites Cho (choline), Cr (creatine), Cr2 (phos-
phocreatine), NAA and (N-acetylaspartate), distributed by the method of linear grouping and 
regional approach, no statistically significant differences were found.
When comparing the values obtained for the Cho metabolite, a statistically significant differ-
ence in the Cho12 index was found: in patients with type 1 diabetes mellitus, 0.82 (0.75–0.84), 
compared with a higher value in the control group, 0.87 (0.81–2.02).
When comparing the tables for the Cr metabolite, statistically significant differences in the 
indices were found: Cr5, Cr10, Cr25, Cr26, Cr28, Cr31, and Cr36.
In the study of the metabolite NAA, no significant differences in voxels were found. The 
study revealed changes in the ratio of metabolites Cho, Cr, Cr2, and NAA.
Thus, the main differences in patients with type 1 diabetes mellitus and in the control group 
were found by the metabolites Cr and Cr2. At the same time, these parameters are energy 
metabolism markers in their function and promote glycolysis [23, 24]. In addition, it was 
reported that in the voxel assessment there are significant differences in Cr and Cr2 in the 
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hippocampus region. This is due to the presence of a concentration gradient of these metabo-
lites between the anterior and posterior parts of the hippocampus in the main group.
5. Conclusion
The central nervous system is one of the key targets for diabetes mellitus, and the disruption 
of which is manifested by cognitive impairment [25]. More recently, it has been shown that 
in patients with diabetes not only the risk of developing dementia is increased but also the 
likelihood of progression from a mild cognitive disorder to Alzheimer’s disease [21]. Chronic 
hyperglycemia and also glucose variability are risk factors for the development of cognitive 
dysfunction, which confirms the need for more severe compensation of the disease. A com-
plex diagnosis of cognitive impairment by studying the neuropsychological status of patients 
is suggested. The markers of cognitive dysfunction-neurospecific proteins and structural 
changes in the magnetic resonance imaging of the brain are studied. The test markers were 
associated with unsatisfactory metabolic control. In addition, the effect of cognitive impair-
ment on QoL of patients with type 1 diabetes mellitus has been shown, especially in cases of 
impaired memory and attention functions. In addition, modern metabolism of the brain was 
studied with the help of the modern MRS method in type 1 diabetes mellitus, and changes 
in the parameters of Cr and Cr2 in the hippocampal region responsible for cognitive changes 
were detected. That confirms the fact of functional changes in the brain in diabetes and in the 
early stages of the disease and can be corrected with the help of rehabilitation measures in the 
form of cognitive training and/or therapeutic physical training.
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